Allt inom mfn_news

Nanexa invites to a webcast to present the positive clinical data from NEX-22 once monthly GLP-1, liraglutide project published on last Friday

Referring to the clinical results presented last Friday Nanexa invites to a webcast hosted by Infront Direkt studios at 14:00 pm today, Monday November 25th.

All Primary and Secondary endpoints met in Nanexa’s Phase I study of the one-month GLP-1 depot NEX-22

Nanexa AB today announce positive results in the company’s Phase I study for NEX-22, long acting GLP-1, in type 2 diabetes. The study evaluates a once-monthly depot formulation of the GLP-1 analog liraglutide with Nanexa’s patented PharmaShell® system.